// App-Quantinova.ai

NIMG-45 : DIFFUSION MRI AS AN EARLY BIOMARKER OF OVERALL SURVIVAL BENEFIT IN RECURRENT GLIOBLASTOMA TREATED WITH IMMUNE CHECKPOINT INHIBITORS

Researchers

Presenter

  • Akifumi Hagiwara

Principal Investigators

  • Yao Jingwen

  • Talia Oughourlian

  • Chencai Wang

  • Catalina Raymond

  • Richard Everson

  • Kunal Patel

  • Sergey Mareninov

  • William Yong

  • Noriko Salamon

  • Whitney Pope

  • Phioanh Nghiemphu

  • Linda Liau

  • Robert Prins

  • Timothy Cloughesy

  • Benjamin Ellingson

Medical Centers

  • University of California Los Angeles, Los Angeles, CA, USA

  • Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Glioblastoma

Biomarkers

  • Apparent diffusion coefficient

Drug/Treatment

  • Pembrolizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved